[HTML][HTML] Diffuse large B-cell lymphoma with involvement of the kidney: outcome and risk of central nervous system relapse
D Villa, JM Connors, LH Sehn, RD Gascoyne… - …, 2011 - ncbi.nlm.nih.gov
Background Renal involvement is uncommon in diffuse large B-cell lymphoma. Recent data
suggest that it is an independent risk factor for central nervous system relapse. We reviewed …
suggest that it is an independent risk factor for central nervous system relapse. We reviewed …
FDG‐PET/CT in the management of lymphomas: current status and future directions
TC El‐Galaly, D Villa, LC Gormsen… - Journal of internal …, 2018 - Wiley Online Library
FDG ‐ PET / CT is the current state‐of‐the‐art imaging in lymphoma and plays a central role
in treatment decisions. At diagnosis, accurate staging is crucial for appropriate therapy …
in treatment decisions. At diagnosis, accurate staging is crucial for appropriate therapy …
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or …
…, J Loscertales, A Avigdor, S Rule, D Villa… - The Lancet …, 2016 - thelancet.com
Background Most patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma
relapse after initial therapy. Bendamustine plus rituximab is often used in the relapsed or …
relapse after initial therapy. Bendamustine plus rituximab is often used in the relapsed or …
Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia
…, R Klasa, AS Gerrie, D Villa - British journal of …, 2015 - Wiley Online Library
Splenic marginal zone lymphoma ( SMZL ) accounts for less than 2% of all non‐Hodgkin
lymphomas. We identified 107 cases diagnosed with SMZL between 1985 and 2012 from the …
lymphomas. We identified 107 cases diagnosed with SMZL between 1985 and 2012 from the …
Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies
…, FE van Leeuwen, G Velikova, D Villa… - The Lancet …, 2018 - thelancet.com
Tremendous progress in treatment and outcomes has been achieved across the whole
range of haematological malignancies in the past two decades. Although cure rates for …
range of haematological malignancies in the past two decades. Although cure rates for …
Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors
…, T Shenkier, R Klasa, LH Sehn, D Villa… - Journal of clinical …, 2013 - ascopubs.org
Introduction A number of novel therapies are under investigation in relapsed or refractory
peripheral T-cell lymphoma (PTCL); however, their relative impact on outcome is unknown. We …
peripheral T-cell lymphoma (PTCL); however, their relative impact on outcome is unknown. We …
CNS international prognostic index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP
…, M Nickelsen, R Kansara, D Villa… - Journal of Clinical …, 2016 - ascopubs.org
Purpose To develop and validate a risk score for relapse in the CNS in patients with diffuse
large B-cell lymphoma (DLBCL). Patients and Methods A total of 2,164 patients (18 to 80 …
large B-cell lymphoma (DLBCL). Patients and Methods A total of 2,164 patients (18 to 80 …
[HTML][HTML] Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell-like diffuse large B-cell lymphoma
…, S Saberi, A Bashashati, D Villa… - Journal of Clinical …, 2019 - ncbi.nlm.nih.gov
Purpose High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (HGBL-DH/TH)
has a poor outcome after standard chemoimmunotherapy. We sought to …
has a poor outcome after standard chemoimmunotherapy. We sought to …
CNS prophylaxis for diffuse large B-cell lymphoma
CNS relapse in the brain parenchyma, eyes, or leptomeninges is an uncommon but
devastating complication of diffuse large B-cell lymphoma. CNS prophylaxis strategies, typically …
devastating complication of diffuse large B-cell lymphoma. CNS prophylaxis strategies, typically …
Phase I study of the CD47 blocker TTI-621 in patients with relapsed or refractory hematologic malignancies
…, RW Chen, IW Flinn, A Sawas, MD Minden, D Villa… - Clinical Cancer …, 2021 - AACR
Purpose: TTI-621 (SIRPα-IgG1 Fc) is a novel checkpoint inhibitor that activates antitumor
activity by blocking the CD47 “don't eat me” signal. This first-in-human phase I study (…
activity by blocking the CD47 “don't eat me” signal. This first-in-human phase I study (…